Relevant markers for overactive bladder laser therapy: nitric oxide and urinary nerve growth factor

To investigate the potential of nitric oxide (NO) and urinary nerve growth factor (NGF) as indicators of therapeutic outcomes in overactive bladder (OAB) patients undergoing low-level laser therapy (LLLT) via a prospective randomized controlled trial. Fifty OAB patients participated in the study and were subjected to LLLT using 650-nm laser irradiation. The study employed a prospective randomized controlled trial design. Nitric oxide and urine NGF levels were assessed before and after the LLLT intervention to evaluate their correlation with therapeutic outcomes. The study provided evidence supporting the effectiveness of LLLT as a treatment modality for OAB. Analysis of NO and urine NGF levels revealed significant changes following LLLT intervention suggesting their potential as biomarkers for assessing therapeutic response in OAB patients. These biomarkers hold promise for aiding clinicians in evaluating treatment response and personalizing therapy approaches for OAB patients. This study highlights the utility of LLLT in managing OAB and underscores the importance of exploring biomarkers such as nitric oxide and urinary nerve growth factor to enhance treatment efficacy assessment. The findings suggest that NO and urine NGF levels may serve as valuable indicators of therapeutic outcomes in OAB patients undergoing LLLT. Further research is warranted to elucidate the underlying mechanisms and optimize the clinical application of LLLT in OAB management.